

September 20, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached press release issued by the Company titled:

**“Strides Shasun receives USFDA Approval
for Omega-3-Acid Ethyl Esters capsules”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary





Press Release

September 20, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076

**Strides Shasun receives USFDA Approval
for Omega-3-Acid Ethyl Esters capsules**

**First Indian Generic Company to receive approval for the generic version of Lovaza®
Product to be marketed through Par Pharmaceutical**

Bangalore, September 20, 2017 Strides Shasun Limited (the Company) today announced that it has received approval from the United States Food & Drug Administration (US FDA) for **Omega-3-Acid Ethyl Esters Softgel capsules**, a generic version of Lovaza.


The US market for the generic Lovaza is approximately USD 300 Million per annum, as per IMS, with five generic players including Par Pharmaceutical (Par), an Endo International Company.

The Company has partnered with Par to market the product in the United States. The product to be manufactured in its flagship facility in Bangalore will be launched immediately.

Shashank Sinha, Managing Director stated, "We are delighted with this important product approval, which came through after a long approval cycle of almost 60 months, due to significant regulatory changes."

About Omega-3-Acid Ethyl Esters capsules

The Company's Omega-3-Acid Ethyl Esters capsules are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia (HTG).



About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u> Shashank Sinha, Managing Director +91 80 6784 0335 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
--	---

*Lovaza is a registered trademark of GlaxoSmithKline LLC

